USPSTF 2021: screening for gestational diabetes
A 2021 statement from the US Preventive Services Task Force advising screening for gestational diabetes in pregnant people without symptoms at 24 weeks of pregnancy or after. For testing before 24 weeks it says the evidence is not enough to judge benefits and harms.
- Guideline
- In this atlas
Overview
Technical summary
USPSTF recommendation statement, JAMA 2021, volume 326, issue 6 (PubMed issue date 2021-08-10). A B recommendation for screening at 24 weeks or after and an I statement before 24 weeks, recorded as claims on the glucose test page. PubMed links an erratum (PMID 34609473, Incorrect Value in Table) whose text was not read. Whether a later edition exists was not checked. The guideline's source is the USPSTF final recommendation statement page, which gives the statement date that the recommendation decisions use; the JAMA statement stays cited in the claims.
About this guideline
- Issued by
- Edition
- USPSTF final recommendation statement, as shown on its page; also published as: Recommendation statement, JAMA 2021;326(6)
- Published
- 2021-08-10
- Status
- Not checked for a newer edition
- Scope
- Pregnant persons who have not been previously diagnosed with type 1 or type 2 diabetes
Source
- Document
- Gestational Diabetes: Screening (USPSTF final recommendation statement page)
- Publisher
- U.S. Preventive Services Task Force
- Edition note
- Final recommendation statement page as fetched on 2026-10-14 (mx-uspstf-gestational-diabetes-screening.html). The date under the title is August 10, 2021.
Recommendations
- Recommended: Glucose tests for gestational diabetes (one-step and two-step)
- Evidence is insufficient to recommend for or against: Glucose tests for gestational diabetes (one-step and two-step)
Record details
- Record id
maternal:guideline-uspstf-2021-gestational-diabetes- Content hash
0360f078048b441c6e00c1ddc6d496849a5c8fd4e3b9eb10758aa4ed88f1653f